These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 33554064)

  • 21. GSK-3beta directly phosphorylates and activates MARK2/PAR-1.
    Kosuga S; Tashiro E; Kajioka T; Ueki M; Shimizu Y; Imoto M
    J Biol Chem; 2005 Dec; 280(52):42715-22. PubMed ID: 16257959
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ER stress is involved in Abeta-induced GSK-3beta activation and tau phosphorylation.
    Resende R; Ferreiro E; Pereira C; Oliveira CR
    J Neurosci Res; 2008 Jul; 86(9):2091-9. PubMed ID: 18335524
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of glycogen synthase kinase-3β by Angelica sinensis extract decreases β-amyloid-induced neurotoxicity and tau phosphorylation in cultured cortical neurons.
    Zhang Z; Zhao R; Qi J; Wen S; Tang Y; Wang D
    J Neurosci Res; 2011 Mar; 89(3):437-47. PubMed ID: 21259330
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tau and GSK-3β are Critical Contributors to α-Synuclein-Mediated Post-Stroke Brain Damage.
    Mehta SL; Kim T; Chelluboina B; Vemuganti R
    Neuromolecular Med; 2023 Mar; 25(1):94-101. PubMed ID: 36447045
    [TBL] [Abstract][Full Text] [Related]  

  • 25. GSK-3 is essential in the pathogenesis of Alzheimer's disease.
    Takashima A
    J Alzheimers Dis; 2006; 9(3 Suppl):309-17. PubMed ID: 16914869
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Stimulation of EphB2 attenuates tau phosphorylation through PI3K/Akt-mediated inactivation of glycogen synthase kinase-3β.
    Jiang J; Wang ZH; Qu M; Gao D; Liu XP; Zhu LQ; Wang JZ
    Sci Rep; 2015 Jun; 5():11765. PubMed ID: 26119563
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Perinatal exposure to lead (Pb) promotes Tau phosphorylation in the rat brain in a GSK-3β and CDK5 dependent manner: Relevance to neurological disorders.
    Gąssowska M; Baranowska-Bosiacka I; Moczydłowska J; Tarnowski M; Pilutin A; Gutowska I; Strużyńska L; Chlubek D; Adamczyk A
    Toxicology; 2016 Mar; 347-349():17-28. PubMed ID: 27012722
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bip enhanced the association of GSK-3β with tau during ER stress both in vivo and in vitro.
    Liu ZC; Fu ZQ; Song J; Zhang JY; Wei YP; Chu J; Han L; Qu N; Wang JZ; Tian Q
    J Alzheimers Dis; 2012; 29(4):727-40. PubMed ID: 22460328
    [TBL] [Abstract][Full Text] [Related]  

  • 29. miR-219-5p inhibits tau phosphorylation by targeting TTBK1 and GSK-3β in Alzheimer's disease.
    Li J; Chen W; Yi Y; Tong Q
    J Cell Biochem; 2019 Jun; 120(6):9936-9946. PubMed ID: 30556160
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Distribution of active glycogen synthase kinase 3beta (GSK-3beta) in brains staged for Alzheimer disease neurofibrillary changes.
    Pei JJ; Braak E; Braak H; Grundke-Iqbal I; Iqbal K; Winblad B; Cowburn RF
    J Neuropathol Exp Neurol; 1999 Sep; 58(9):1010-9. PubMed ID: 10499443
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The active form of glycogen synthase kinase-3beta is associated with granulovacuolar degeneration in neurons in Alzheimer's disease.
    Leroy K; Boutajangout A; Authelet M; Woodgett JR; Anderton BH; Brion JP
    Acta Neuropathol; 2002 Feb; 103(2):91-9. PubMed ID: 11810173
    [TBL] [Abstract][Full Text] [Related]  

  • 32. miR-23b-3p rescues cognition in Alzheimer's disease by reducing tau phosphorylation and apoptosis via GSK-3β signaling pathways.
    Jiang H; Liu J; Guo S; Zeng L; Cai Z; Zhang J; Wang L; Li Z; Liu R
    Mol Ther Nucleic Acids; 2022 Jun; 28():539-557. PubMed ID: 35592504
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increased level of active GSK-3beta in Alzheimer's disease and accumulation in argyrophilic grains and in neurones at different stages of neurofibrillary degeneration.
    Leroy K; Yilmaz Z; Brion JP
    Neuropathol Appl Neurobiol; 2007 Feb; 33(1):43-55. PubMed ID: 17239007
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Loss of biliverdin reductase-A favors Tau hyper-phosphorylation in Alzheimer's disease.
    Sharma N; Tramutola A; Lanzillotta C; Arena A; Blarzino C; Cassano T; Butterfield DA; Di Domenico F; Perluigi M; Barone E
    Neurobiol Dis; 2019 May; 125():176-189. PubMed ID: 30738142
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cornel Iridoid Glycoside Inhibits Tau Hyperphosphorylation via Regulating Cross-Talk Between GSK-3β and PP2A Signaling.
    Yang C; Li X; Gao W; Wang Q; Zhang L; Li Y; Li L; Zhang L
    Front Pharmacol; 2018; 9():682. PubMed ID: 29997510
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of glycogen synthase kinase-3 reverses tau hyperphosphorylation induced by Pin1 down-regulation.
    Xiong YS; Wang DL; Tan L; Wang X; Chen LM; Gong CX; Wang JZ; Zhu LQ
    CNS Neurol Disord Drug Targets; 2013 May; 12(3):436-43. PubMed ID: 23469846
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discovery of Selective, Substrate-Competitive, and Passive Membrane Permeable Glycogen Synthase Kinase-3β Inhibitors: Synthesis, Biological Evaluation, and Molecular Modeling of New C-Glycosylflavones.
    Liang Z; Li QX
    ACS Chem Neurosci; 2018 May; 9(5):1166-1183. PubMed ID: 29381861
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Glycogen synthase kinase-3beta phosphorylates protein tau and rescues the axonopathy in the central nervous system of human four-repeat tau transgenic mice.
    Spittaels K; Van den Haute C; Van Dorpe J; Geerts H; Mercken M; Bruynseels K; Lasrado R; Vandezande K; Laenen I; Boon T; Van Lint J; Vandenheede J; Moechars D; Loos R; Van Leuven F
    J Biol Chem; 2000 Dec; 275(52):41340-9. PubMed ID: 11007782
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Alzheimer's disease-like phosphorylation of the microtubule-associated protein tau by glycogen synthase kinase-3 in transfected mammalian cells.
    Lovestone S; Reynolds CH; Latimer D; Davis DR; Anderton BH; Gallo JM; Hanger D; Mulot S; Marquardt B; Stabel S
    Curr Biol; 1994 Dec; 4(12):1077-86. PubMed ID: 7704571
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chronic lithium administration to FTDP-17 tau and GSK-3beta overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre-formed neurofibrillary tangles do not revert.
    Engel T; Goñi-Oliver P; Lucas JJ; Avila J; Hernández F
    J Neurochem; 2006 Dec; 99(6):1445-55. PubMed ID: 17059563
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.